USA Drug Delivery Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Route of Administration (Topical Injectable, Oral, Nasal, Others), And By Application (Treatment of Diseases, Research/Academic Purposes) - Forecasts From 2022 To 2027

The USA drug delivery market is projected to grow at a CAGR of 6.92% during the forecast period. The method or process of providing a pharmaceutical substance to achieve a therapeutic effect on individuals or animals is referred to as drug delivery. In the treatment of human diseases, the nasal and pulmonary routes of pharmaceutical administration are becoming increasingly significant. These techniques, particularly for peptide and protein therapeutics, present fascinating alternatives to parenteral drug delivery. Several drug delivery methods have been developed for this purpose and are being tested for nasal and pulmonary delivery. Liposomes, proliposomes, microspheres, gels, prodrugs, and cyclodextrins are only a few examples. The USA drug delivery market is segmented by route of administration, and application.

Factors such as the rising prevalence of chronic diseases and advancements in drug delivery systems are projected to drive market expansion.

According to the Center for Disease Control and Prevention, approximately six out of ten adults in the United States have a chronic disease, and four out of ten adults have two or more chronic diseases. Physical inactivity, a high-sugar diet, drinking, smoking, and other lifestyle changes are all contributing to the disease's rising burden in the United States. According to the Centers for Disease Control and Prevention, physical inactivity in the United States ranges from 17.3 to 47.7 percent in 2020. Furthermore, more than 34 million people in the country have diabetes, and one out of every four of them is unaware of it.

According to the American Cancer Society, 1.9 million new cancer cases and 608,570 cancer deaths were estimated to be reported in the United States in 2021. Advancements in cancer drug delivery systems are projected to propel market expansion even more. A research team from the Department of Energy's Pacific Northwest National Laboratory (PNNL) and Washington State University developed cancer-treatment medication delivery technology in 2019.

According to CDC, only one out of every four US adults and one out of every five high school kids achieve the recommended physical activity standards. Around 31 million people aged 50 and up are inactive, meaning they do not engage in any physical activity outside of their everyday routine. Heart disease, type 2 diabetes, a variety of cancers, and obesity are all linked to it. Low levels of physical activity are also linked to an annual expenditure of US$117 billion in health care. Prediabetes affects more than 84 million persons in the United States, or one in every three, and 90 percent of them are unaware of their condition. Obesity and a lack of physical activity are the top avoidable risk factors for prediabetes and type 2 diabetes.

Many firms are concentrating efforts on the launch of new items that will help in market expansion. For example, Mylan announced the launch of its adalimumab biosimilar in July 2019. Adalimumab is an injectable biologic medication that inhibits Tumor Necrosis Factor (TNF) and is used to treat a number of autoimmune illnesses including rheumatic, dermatological, and gastroenterological. Similarly, Sandoz, a Novartis company and a global leader in biosimilars, got European Commission clearance for HYRIMOZ, an adalimumab biosimilar, for subcutaneous injection in either a syringe or a prefilled pen in Spain in February 2019. Becton, Dickinson and Company declared in May 2021 that it would build a medicine delivery device manufacturing facility in Zaragoza, Spain, for US$200 million. In addition, Novartis announced in January 2021 that it has invested in the American company, Credence MedSystems, to help develop and scale up its drug delivery systems.

The market's growth may be hampered by frequent rules and guideline modifications for combination products.

In terms of the regulatory stance, regulatory authorities have established strict guidelines for the approval of combination products. Manufacturers find it difficult to launch new products and serve the needs of patients due to the continuous changes in the laws. For instance, the US FDA issued new guidance for product development and quality evaluation of transdermal and topical administration systems in November 2019. Similarly, it provided proposed recommendations in December 2021 for transferring medical devices with EUAs during pandemics.

Covid-19 Insights

Covid-19 had a positive impact on the USA drug delivery market. In the first quarter of 2020, several organizations had a rise in sales as compared to the first quarter of 2019. AbbVie, for example, saw a 16.8 percent growth in sales in the first quarter of 2020 compared to the same period in 2019. Amgen Inc., on the other hand, recorded revenue of US$6,161 million in the first quarter of 2020, an increase of 11% over the same period last year. According to the IQVIA Global Use of Medicine 2020 research, by the end of 2022, the amount of money spent on buying medicines around the world is expected to surpass USD 1.4 trillion. The pandemic has also opened up several new market prospects. With the rapid development of COVID-19 therapeutics and vaccines, one route for researchers aiming to improve these medicines is to look into other drug delivery systems. Scientists at the University of Pennsylvania and the biotech firm Regeneron, for instance, are examining whether gene therapy techniques are useful in creating a nasal spray that prevents infection with the new coronavirus. To satisfy the rising demand for COVID-19 vaccinations, companies are attempting to increase the production of prefilled syringes. For example, in May 2020, the US Department of Defense approved ApiJect Systems America a US$138 million contract for Project Jumpstart and RAPID USA to assist with the production of coronavirus vaccine prefilled syringes. The prefilled syringe supply chain benefited from Project Jumpstart as it produced 100 million prefilled syringes in 2020.

USA Drug Delivery Market Scope:

Key Market Segments

• By Route of Administration
  • Topical
  • Injectable
  • Oral
  • Nasal
  • Others
• By Application
  • Treatment of diseases
  • Research/Academic purposes

AstraZeneca

West Pharmaceutical Services, Inc.

Becton, Dickinson and Company

Medtronic

Merck & Co. Inc.

Antares Pharma

3M (Kindeva Drug Delivery)

Aquestive therapeutics

Eli Lilly and Company

Enable Injections

CURE Pharmaceutical

Catalent, Inc.